+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial



Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial



Addiction Biology 21(4): 904-914



Evidence suggests that the norepinephrine system represents an important treatment target for alcohol dependence (AD) and the α1 -blocker prazosin may reduce alcohol drinking in rodents and alcoholic patients. The α1 -blocker doxazosin demonstrates a more favorable pharmacokinetic profile than prazosin, but has never been studied for AD. A double-blind placebo-controlled randomized clinical trial was conducted in AD individuals seeking outpatient treatment. Doxazosin or matched placebo was titrated to 16 mg/day (or maximum tolerable dose). Drinks per week (DPW) and heavy drinking days (HDD) per week were the primary outcomes. Family history density of alcoholism (FHDA), severity of AD and gender were a priori moderators. Forty-one AD individuals were randomized, 30 (doxazosin = 15) completed the treatment phase and 28 (doxazosin = 14) also completed the follow-up. There were no significant differences between groups on DPW and HDD per week. With FHDA as a moderator, there were significant FHDA × medication interactions for both DPW (pcorrected  = 0.001, d = 1.18) and HDD (pcorrected  = 0.00009, d = 1.30). Post hoc analyses revealed that doxazosin significantly reduced alcohol drinking in AD patients with high FHDA and by contrast increased drinking in those with low FHDA. Doxazosin may be effective selectively in AD patients with high FHDA. This study provides preliminary evidence for personalized medicine using α1 -blockade to treat AD. However, confirmatory studies are required.

(PDF emailed within 0-6 h: $19.90)

Accession: 058791554

Download citation: RISBibTeXText

PMID: 26037245

DOI: 10.1111/adb.12275


Related references

Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial. European Journal of Pain 22(7): 1321-1330, 2018

Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant. Acta Dermato-Venereologica 98(1): 26-31, 2017

Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan. Trials 20(1): 164, 2019

Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an α-blocker (tamsulosin): study protocol for a randomized controlled trial. Trials 15: 238, 2015

Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology 231(17): 3647-3662, 2015

Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. Alzheimer's and Dementia 4: 173-181, 2018

Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder Proof-of-Concept. Neuropsychopharmacology, 2013

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 144(2): 411-419, 2014

A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study. Chest 152(2): 368-378, 2017

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. Journal of Psychopharmacology 30(5): 428-435, 2017

Do occlusal splints have an effect on complex regional pain syndrome? A randomized, controlled proof-of-concept trial. Clinical Journal of Pain 24(9): 776-783, 2008

Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. Journal of Traumatic Stress 20(6): 923-932, 2007

A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder. American Journal on Addictions 25(2): 94-98, 2016

A randomized, placebo-controlled proof-of-concept, crossover trial of phenytoin for hydrocortisone-induced declarative memory changes. Journal of Affective Disorders 150(2): 551-558, 2014

Indocyanine green-augmented diode laser therapy of telangiectatic leg veins: a randomized controlled proof-of-concept trial. Lasers in Surgery and Medicine 44(5): 369-376, 2012